Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

EPFL researchers have developed a computational method to explicitly consider the impact of water while designing membrane ...

Furthermore, unlike receptor-focused GIPR antagonists, HCR-188 binds circulating GIP ligand, which is expressed exclusively ...

The development of nanodrugs targeting multidrug-resistant bacteria, while sparing the beneficial constituents of the microbiome, has emerged as a promising approach to combat disease and curb the ...

The strength of theoretical approaches is in the simplification of complex biological systems. We here consider the general problem of receptor–ligand binding in the context of antibody–antigen ...

Innovative designs of GPCRs with enhanced signaling and stability offer new insights for drug discovery and synthetic biology ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Announcing a new publication for Acta Materia Medica journal. Single-cell RNA sequencing (scRNA-seq) data from published datasets were obtained to investigate the expression and dysregulation of ...

Researchers have developed a computational method to explicitly consider the impact of water while designing membrane receptors with enhanced stability and signaling, paving the way for novel drug ...